A Phase 2 study of concurrent combination therapy of TFTD (TAS-102) and bevacizumab in patients of more than 70 years of age with unresectable, advanced/recurrent colorectal cancer (KSCC 1602)

Interventions: TFTD 35 mg/m2, po, bid at day 1-5 and day 8-12 and bevacizumab 5mg/kg, iv, every 2 weeks are concurrently administered. The administration is continued until the meeting of discontinuation criteria as 1 course of 28 days.
Primary outcome(s): Progression-Free Survival
Study Design: Single arm Non-randomized

干预措施：同时给予曲氟尿苷替匹嘧啶（TFTD）35 mg/m²，口服（po），每日2次（bid），于第1~5天及第8~12天给药，以及贝伐珠单抗（bevacizumab）5 mg/kg，静脉输注（iv），每2周给药1次。以28天为一个疗程，持续给药直至符合停药标准。
主要终点：无进展生存期（Progression-Free Survival）
试验设计：单臂非随机试验